ADIAL PHARMACEUTICALS INC (ADIL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.15+6.68%
Close 2026-11-03 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ADIL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Azora expects to advance AT177 into a Phase 1 clinical trial in the first half of 2027.
Stated in 1 of 2 supplied quarters. Management reported: “With strong progress across our preclinical and CMC programs, we remain on track to file an IND in the first half of 2027.”” “Azora expects to advance AT177 into a Phase 1 clinical trial in the first half of 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“With strong progress across our preclinical and CMC programs, we remain on track to file an IND in the first half of 2027.””
Following these transactions, Azora’s current cash and cash equivalents are expected to fund current operational plans into 2028, including IND-enabling studies and the initiation of the Phase 1 clin…
Stated in 1 of 2 supplied quarters. Management reported: “The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2027.” “Following these transactions, Azora’s current cash and cash equivalents are expected to fund current operational plans into 2028, including IND-enabling studies and the initiation of the Phase 1 clinical trial in UC.”
“The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2027.”
“From a strategic standpoint, we were also pleased to establish a collaboration framework with Molteni Farmaceutici, which represents an important first step toward building a commercial pathway for…
Stated in 1 of 2 supplied quarters. Management reported: ““From a strategic standpoint, we were also pleased to establish a collaboration framework with Molteni Farmaceutici, which represents an important first step toward building a commercial pathway for AD04 in Europe, subject to the execution of a definitive agreement.”
““From a strategic standpoint, we were also pleased to establish a collaboration framework with Molteni Farmaceutici, which represents an important first step toward building a commercial pathway for…”
Continue building AD04 patent protection, including the international patent application management said could extend protection through at least 2045 if granted.
Continue regulatory and clinical planning for AD04, including a potential Phase 3 program for alcohol use disorder, subject to adequate funding.
Over the trailing year it converted 0.48x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
34 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.